References
- Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J 2012;14(2):296-302
- Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 2009;73(5):372-7
- Paolicelli D, D'Onghia M, Pellegrini F, et al. The impact of neutralizing antibodies on the risk of disease worsening in interferon beta-treated relapsing multiple sclerosis: a 5 year post-marketing study. J Neurol 2013;260(6):1562-8
- Cohen BA, Oger J, Gagnon A, Giovannoni G. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci 2008;275(1-2):7-17
- Grossberg SE, Oger J, Grossberg LD, et al. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis. J Interferon Cytokine Res 2011;31(3):337-44
- Hegen H, Millonig A, Bertolotto A, et al. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Mult Scler 2014;20(5):577-87
- Hegen H, Schleiser M, Gneiss C, et al. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler 2012;18(5):610-15
- Jensen PE, Koch-Henriksen N, Sellebjerg F, Sorensen PS. Prediction of antibody persistency from antibody titres to natalizumab. Mult Scler 2012;18(10):1493-9
- Lundkvist M, Engdahl E, Holmen C, et al. Characterization of anti-natalizumab antibodies in multiple sclerosis patients. Mult Scler 2013;19(6):757-64
- Sorensen PS, Jensen PE, Haghikia A, et al. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler 2011;17(9):1074-8
- Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 2013;19(5):593-600
- Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol 2014. [Epub ahead of print]
- Somerfield J, Hill-Cawthorne GA, Lin A, et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol 2010;185(1):763-8
- Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010;9(7):740-50
- Jungedal R, Lundkvist M, Engdahl E, et al. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. Mult Scler 2012;18(12):1775-81